vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and MEDALLION FINANCIAL CORP (MFIN). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $70.6M, roughly 2.0× MEDALLION FINANCIAL CORP). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 17.3%, a 18.2% gap on every dollar of revenue. On growth, MEDALLION FINANCIAL CORP posted the faster year-over-year revenue change (25.4% vs 18.4%). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 15.0%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Mahindra & Mahindra Financial Services Limited (MMFSL) is an Indian rural non-banking financial company headquartered in Mumbai. It is amongst the top tractor financers in India, with 1000+ offices across the country.
ADMA vs MFIN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $70.6M |
| Net Profit | $49.4M | $12.2M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 29.3% |
| Net Margin | 35.5% | 17.3% |
| Revenue YoY | 18.4% | 25.4% |
| Net Profit YoY | -55.9% | 20.3% |
| EPS (diluted) | $0.20 | $0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $70.6M | ||
| Q3 25 | $134.2M | $58.7M | ||
| Q2 25 | $122.0M | $62.6M | ||
| Q1 25 | $114.8M | $63.0M | ||
| Q4 24 | $117.5M | $56.3M | ||
| Q3 24 | $119.8M | $53.3M | ||
| Q2 24 | $107.2M | $51.0M | ||
| Q1 24 | $81.9M | $53.3M |
| Q4 25 | $49.4M | $12.2M | ||
| Q3 25 | $36.4M | $7.8M | ||
| Q2 25 | $34.2M | $11.1M | ||
| Q1 25 | $26.9M | $12.0M | ||
| Q4 24 | $111.9M | $10.1M | ||
| Q3 24 | $35.9M | $8.6M | ||
| Q2 24 | $32.1M | $7.1M | ||
| Q1 24 | $17.8M | $10.0M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | 29.3% | ||
| Q3 25 | 38.0% | 33.2% | ||
| Q2 25 | 35.1% | 31.1% | ||
| Q1 25 | 30.4% | 32.1% | ||
| Q4 24 | 32.6% | 32.8% | ||
| Q3 24 | 33.1% | 26.6% | ||
| Q2 24 | 36.6% | 24.3% | ||
| Q1 24 | 26.7% | 33.6% |
| Q4 25 | 35.5% | 17.3% | ||
| Q3 25 | 27.1% | 13.2% | ||
| Q2 25 | 28.1% | 17.7% | ||
| Q1 25 | 23.4% | 19.1% | ||
| Q4 24 | 95.2% | 18.0% | ||
| Q3 24 | 30.0% | 16.1% | ||
| Q2 24 | 29.9% | 13.9% | ||
| Q1 24 | 21.7% | 18.8% |
| Q4 25 | $0.20 | $0.50 | ||
| Q3 25 | $0.15 | $0.32 | ||
| Q2 25 | $0.14 | $0.46 | ||
| Q1 25 | $0.11 | $0.50 | ||
| Q4 24 | $0.45 | $0.43 | ||
| Q3 24 | $0.15 | $0.37 | ||
| Q2 24 | $0.13 | $0.30 | ||
| Q1 24 | $0.08 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $136.3M |
| Total DebtLower is stronger | $72.1M | $216.0M |
| Stockholders' EquityBook value | $477.3M | $408.6M |
| Total Assets | $624.2M | $3.0B |
| Debt / EquityLower = less leverage | 0.15× | 0.53× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $136.3M | ||
| Q3 25 | $61.4M | $72.5M | ||
| Q2 25 | $90.3M | $110.4M | ||
| Q1 25 | $71.6M | $131.5M | ||
| Q4 24 | $103.1M | $98.2M | ||
| Q3 24 | $86.7M | $120.6M | ||
| Q2 24 | $88.2M | $87.7M | ||
| Q1 24 | $45.3M | $54.8M |
| Q4 25 | $72.1M | $216.0M | ||
| Q3 25 | $72.4M | $215.7M | ||
| Q2 25 | — | $199.9M | ||
| Q1 25 | — | $199.7M | ||
| Q4 24 | $72.3M | $232.2M | ||
| Q3 24 | — | $232.0M | ||
| Q2 24 | — | $230.8M | ||
| Q1 24 | — | $225.6M |
| Q4 25 | $477.3M | $408.6M | ||
| Q3 25 | $431.2M | $397.4M | ||
| Q2 25 | $398.3M | $389.9M | ||
| Q1 25 | $373.4M | $380.2M | ||
| Q4 24 | $349.0M | $370.2M | ||
| Q3 24 | $231.9M | $362.4M | ||
| Q2 24 | $188.3M | $354.0M | ||
| Q1 24 | $153.7M | $349.0M |
| Q4 25 | $624.2M | $3.0B | ||
| Q3 25 | $568.7M | $2.9B | ||
| Q2 25 | $558.4M | $2.9B | ||
| Q1 25 | $510.6M | $2.8B | ||
| Q4 24 | $488.7M | $2.9B | ||
| Q3 24 | $390.6M | $2.9B | ||
| Q2 24 | $376.4M | $2.8B | ||
| Q1 24 | $350.9M | $2.6B |
| Q4 25 | 0.15× | 0.53× | ||
| Q3 25 | 0.17× | 0.54× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 0.53× | ||
| Q4 24 | 0.21× | 0.63× | ||
| Q3 24 | — | 0.64× | ||
| Q2 24 | — | 0.65× | ||
| Q1 24 | — | 0.65× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $126.3M |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 0.72× | 10.35× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $126.3M | ||
| Q3 25 | $13.3M | $67.0M | ||
| Q2 25 | $21.1M | $-10.7M | ||
| Q1 25 | $-19.7M | $36.3M | ||
| Q4 24 | $50.2M | $108.7M | ||
| Q3 24 | $25.0M | $24.6M | ||
| Q2 24 | $45.6M | $27.6M | ||
| Q1 24 | $-2.2M | $32.3M |
| Q4 25 | $34.6M | — | ||
| Q3 25 | $-1.1M | — | ||
| Q2 25 | $18.7M | — | ||
| Q1 25 | $-24.4M | — | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $24.0M | — | ||
| Q2 24 | $43.6M | — | ||
| Q1 24 | $-4.6M | — |
| Q4 25 | 24.8% | — | ||
| Q3 25 | -0.8% | — | ||
| Q2 25 | 15.3% | — | ||
| Q1 25 | -21.2% | — | ||
| Q4 24 | 40.4% | — | ||
| Q3 24 | 20.0% | — | ||
| Q2 24 | 40.7% | — | ||
| Q1 24 | -5.6% | — |
| Q4 25 | 0.8% | — | ||
| Q3 25 | 10.7% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 4.1% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 1.9% | — | ||
| Q1 24 | 2.9% | — |
| Q4 25 | 0.72× | 10.35× | ||
| Q3 25 | 0.36× | 8.63× | ||
| Q2 25 | 0.62× | -0.97× | ||
| Q1 25 | -0.73× | 3.02× | ||
| Q4 24 | 0.45× | 10.72× | ||
| Q3 24 | 0.70× | 2.86× | ||
| Q2 24 | 1.42× | 3.89× | ||
| Q1 24 | -0.12× | 3.22× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
MFIN
Segment breakdown not available.
